ArticleMovement disorders : official journal of the Movement Disorder Society2025
Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa-Foscarbidopa Hydrate: Histopathology.
Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Frailty in Parkinson's disease: time to integrate it into treatment decision-making?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease.Movement disorders clinical practice · 2026Review
- Ultrasonographic Detection of Fluid Collection in Parkinson's Disease Patients on Subcutaneous Infusion Therapy.Movement disorders clinical practice · 2026Article
- Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real-World Short-Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication.Movement disorders clinical practice · 2025Article
- Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO).Movement disorders clinical practice · 2025Observational
- Neutrophil-Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa.Movement disorders : official journal of the Movement Disorder Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.